HK1207295A1 - Transmucosal delivery of tocotrienol - Google Patents

Transmucosal delivery of tocotrienol

Info

Publication number
HK1207295A1
HK1207295A1 HK15107895.4A HK15107895A HK1207295A1 HK 1207295 A1 HK1207295 A1 HK 1207295A1 HK 15107895 A HK15107895 A HK 15107895A HK 1207295 A1 HK1207295 A1 HK 1207295A1
Authority
HK
Hong Kong
Prior art keywords
tocotrienol
transmucosal delivery
transmucosal
delivery
Prior art date
Application number
HK15107895.4A
Other languages
English (en)
Chinese (zh)
Inventor
童 格倫
Original Assignee
Gordagen Pharmaceuticals Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012904937A external-priority patent/AU2012904937A0/en
Application filed by Gordagen Pharmaceuticals Pty Ltd filed Critical Gordagen Pharmaceuticals Pty Ltd
Publication of HK1207295A1 publication Critical patent/HK1207295A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK15107895.4A 2012-11-13 2015-08-14 Transmucosal delivery of tocotrienol HK1207295A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2012904937A AU2012904937A0 (en) 2012-11-13 Sublingual and buccal delivery of tocotrienol derivatives as therapeutic agents
AU2012905406A AU2012905406A0 (en) 2012-12-11 Sublingual and buccal delivery of tocotrienol derivatives as therapeutic agents
PCT/AU2013/001310 WO2014075135A1 (en) 2012-11-13 2013-11-13 Transmucosal delivery of tocotrienol

Publications (1)

Publication Number Publication Date
HK1207295A1 true HK1207295A1 (en) 2016-01-29

Family

ID=50730398

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15107895.4A HK1207295A1 (en) 2012-11-13 2015-08-14 Transmucosal delivery of tocotrienol

Country Status (23)

Country Link
US (2) US10675265B2 (xx)
EP (1) EP2919777B1 (xx)
JP (3) JP6460998B2 (xx)
KR (1) KR20150082109A (xx)
CN (2) CN112451518A (xx)
AU (1) AU2013344817B2 (xx)
BR (1) BR112015010703B1 (xx)
CA (1) CA2891164C (xx)
DK (1) DK2919777T3 (xx)
ES (1) ES2778065T3 (xx)
HK (1) HK1207295A1 (xx)
IL (1) IL238727A0 (xx)
IN (1) IN2015DN04006A (xx)
MY (1) MY177940A (xx)
NZ (1) NZ628963A (xx)
PE (1) PE20151518A1 (xx)
PH (1) PH12015501048A1 (xx)
PL (1) PL2919777T3 (xx)
PT (1) PT2919777T (xx)
RU (1) RU2015120181A (xx)
SG (1) SG11201503640WA (xx)
WO (1) WO2014075135A1 (xx)
ZA (1) ZA201504191B (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
PT2919777T (pt) * 2012-11-13 2020-03-30 Invictus Biotechnology Pty Ltd Distribuição transmucosa de tocotrienol
US9898585B2 (en) 2014-01-31 2018-02-20 Aseko, Inc. Method and system for insulin management
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
EP3050023B1 (en) 2014-10-27 2021-08-25 Aseko, Inc. Subcutaneous outpatient management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
WO2017025808A1 (en) * 2015-08-11 2017-02-16 Satoru Sugiyama System and method for improved blood circulation and maintaining mitochondrial energy production
WO2017031440A1 (en) 2015-08-20 2017-02-23 Aseko, Inc. Diabetes management therapy advisor
US11612613B2 (en) 2017-08-08 2023-03-28 Robert Petcavich Formulations for the delivery of autophagy stimulating Trehalose
CN117098556A (zh) * 2020-12-04 2023-11-21 因维克特斯生物技术有限公司 生育三烯酚的经粘膜递送

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07504887A (ja) * 1991-11-22 1995-06-01 リポジェニックス，インコーポレイテッド トコトリエノールおよびトコトリエノール様化合物ならびにこれらを使用する方法
JPH0892050A (ja) 1994-09-27 1996-04-09 Lion Corp 消臭剤及び口腔用組成物
JP4271742B2 (ja) 1997-08-07 2009-06-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 免疫機能改善剤
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
ES2346181T3 (es) 2000-03-31 2010-10-13 EISAI R&D MANAGEMENT CO., LTD. Uso de gamma-tocotrienol como diuretico.
JP2001342133A (ja) 2000-03-31 2001-12-11 Eisai Co Ltd γ―トコトリエノール含有利尿剤
JP2002037727A (ja) 2000-07-26 2002-02-06 Eisai Co Ltd 脂溶性薬物を配合した速崩性固形製剤及びその製造方法
JP4693140B2 (ja) 2000-10-06 2011-06-01 富士化学工業株式会社 トコトリエノール含有医薬用剤
US6608103B2 (en) * 2001-02-08 2003-08-19 Fuji Chemical Industry Co., Ltd. Inhibitor for neovasculation, cell multiplication, lumen formation and FGF
JP4447198B2 (ja) 2001-02-08 2010-04-07 富士化学工業株式会社 トコトリエノールを有効成分とする血管新生阻害剤、細胞増殖阻害剤、管腔形成阻害剤及びｆｇｆ阻害剤並びに食品或いは食品添加物
JP4903558B2 (ja) 2003-02-14 2012-03-28 ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディシン，インコーポレイティド ガンマ−トコトリエノールによる放射線防護
ES2505252T3 (es) 2003-04-10 2014-10-09 Barrie Tan Composiciones de extracto de achiote que incluyen tocotrienoles y tocoferoles y métodos de uso
US20050209315A1 (en) * 2004-03-20 2005-09-22 Papas Andreas M Bioavailable nutritional supplement and method of treatment of malabsorption
DE602005025339D1 (de) * 2004-05-26 2011-01-27 Kgk Synergize Inc Flavonoide und Tocotrienole enthaltende Zusammensetzungen und deren Verwendungen
CN1775289B (zh) 2004-11-15 2011-08-24 杭州赛诺菲民生健康药业有限公司 多维生素口腔崩解片制剂及其制备方法
JP5613657B2 (ja) 2008-03-28 2014-10-29 ヘイル バイオファーマ ベンチャーズ，エルエルシー ベンゾジアゼピン組成物の投与
WO2009126866A2 (en) 2008-04-10 2009-10-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Delta-tocotrienol as a radioprotective countermeasure agent
AU2010262738A1 (en) 2009-05-20 2011-10-13 Lingual Consegna Pty Ltd Buccal and/or sublingual therapeutic formulation
MX2011013558A (es) 2009-06-25 2012-04-30 Ampere Life Sciences Inc Tratamiento del trastorno pervasivo del desarrollo con tocotrienoles o extractos de tocotrienoles enriquecidos.
NO2470168T3 (xx) * 2009-08-26 2018-06-30
EP2519232A1 (en) 2009-12-31 2012-11-07 Edison Pharmaceuticals, Inc. Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
AU2011238525A1 (en) 2010-04-06 2012-11-08 Edison Pharmaceuticals, Inc. Treatment of Ataxia Telangiectasia
US20120295985A1 (en) 2010-11-19 2012-11-22 Miller Guy M Methods for improving blood glucose control
AU2011323059B2 (en) 2011-02-18 2013-02-21 Biolingus Ip Llc Process for preparing products comprising stabilised actives and compositions comprising same
EP4085899A1 (en) 2011-06-14 2022-11-09 Neurelis, Inc. Administration of benzodiazepine
PT2919777T (pt) * 2012-11-13 2020-03-30 Invictus Biotechnology Pty Ltd Distribuição transmucosa de tocotrienol

Also Published As

Publication number Publication date
ZA201504191B (en) 2016-11-30
EP2919777A4 (en) 2016-05-18
US20200246306A1 (en) 2020-08-06
BR112015010703A2 (pt) 2017-07-11
US11331302B2 (en) 2022-05-17
CA2891164A1 (en) 2014-05-22
EP2919777A1 (en) 2015-09-23
IL238727A0 (en) 2015-06-30
JP6460998B2 (ja) 2019-01-30
BR112015010703B1 (pt) 2021-02-17
MY177940A (en) 2020-09-28
JP2021008509A (ja) 2021-01-28
PH12015501048A1 (en) 2015-07-27
JP2016503407A (ja) 2016-02-04
EP2919777B1 (en) 2020-01-08
US20150265570A1 (en) 2015-09-24
PL2919777T3 (pl) 2020-07-13
JP2019031504A (ja) 2019-02-28
NZ628963A (en) 2017-02-24
AU2013344817A1 (en) 2015-02-12
WO2014075135A1 (en) 2014-05-22
ES2778065T3 (es) 2020-08-07
PT2919777T (pt) 2020-03-30
DK2919777T3 (da) 2020-03-09
SG11201503640WA (en) 2015-06-29
BR112015010703A8 (pt) 2018-08-14
US10675265B2 (en) 2020-06-09
CN104582700A (zh) 2015-04-29
JP6978392B2 (ja) 2021-12-08
CN112451518A (zh) 2021-03-09
CA2891164C (en) 2021-02-09
AU2013344817B2 (en) 2015-09-17
RU2015120181A (ru) 2017-01-10
IN2015DN04006A (xx) 2015-10-02
PE20151518A1 (es) 2015-11-25
KR20150082109A (ko) 2015-07-15
CN104582700B (zh) 2021-01-05

Similar Documents

Publication Publication Date Title
HK1215817A1 (zh) 內容遞送框架
HK1207295A1 (en) Transmucosal delivery of tocotrienol
HK1208155A1 (en) Transmucosal delivery of engineered polypeptides
IL236268B (en) Preparations for mucosal administration and their uses
GB2503668B (en) Delivery apparatus
EP2810070A4 (en) EXTRACTION OF MYCOTOXINS
GB2507485B (en) Lead delivery apparatus
HK1214523A1 (zh) 醋酸格拉替雷的透粘膜給藥
GB201213491D0 (en) Content delivery system
SG10201609440WA (en) Multi-additive delivery system
HK1197062A1 (en) Chromene compound
PL2908837T3 (pl) Kompozycje do dostarczania leku
EP2911420A4 (en) CONTENTS ISSUE PROCEDURE
EP2821404A4 (en) CHROMANE DERIVATIVE
GB201218012D0 (en) Dosage forms
EP2839418A4 (en) LOTTERY ADVERTISING
HK1183226A1 (en) Drug package
EP2768486A4 (en) TOCOTRIENOL COMPOSITIONS
HUE047982T2 (hu) Szinterelt üvegtermék
GB201208751D0 (en) Anti-malarial compounds
GB201216518D0 (en) Convienance cup
AU346861S (en) Bracket
AU345987S (en) Bracket
GB201210511D0 (en) Parcel delivery solution
TWM433160U (en) Cup structure improvement